||Rapid Review Complete
||For the treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of imipenem/cilastatin/relebactam compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.